BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olivera P, Danese S, Peyrin-biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut 2017;66:199-209. [DOI: 10.1136/gutjnl-2016-312912] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Al-shamma H, Lehmann-bruinsma K, Carroll C, Solomon M, Komori HK, Peyrin-biroulet L, Adams J. The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis. J Pharmacol Exp Ther 2019;369:311-7. [DOI: 10.1124/jpet.118.254268] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
2 Sandborn WJ, Peyrin-biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology 2020;158:550-61. [DOI: 10.1053/j.gastro.2019.10.035] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 18.5] [Reference Citation Analysis]
3 Na SY, Moon W. Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut Liver. 2019;13:604-616. [PMID: 31195433 DOI: 10.5009/gnl19019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
4 Maida M, Morreale GC, Sferrazza S, Sinagra E, Scalisi G, Vitello A, Vettori G, Rossi F, Catarella D, Di Bartolo CE, Schillaci D, Raimondo D, Camilleri S, Orlando A, Macaluso FS. Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases. Dig Liver Dis 2021;53:1171-7. [PMID: 33994129 DOI: 10.1016/j.dld.2021.04.006] [Reference Citation Analysis]
5 Hernandez-rocha C, Vande Casteele N. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:99-109. [DOI: 10.1016/j.coph.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
7 Sun M, Zhou Y, Shi Y, Liu B. Effect of the Sphingosine Kinase 1 Selective Inhibitor, PF543 on Dextran Sodium Sulfate-Induced Colitis in Mice. DNA Cell Biol 2019;38:1338-45. [PMID: 31464523 DOI: 10.1089/dna.2019.4737] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Fiorino G, D'Amico F, Italia A, Gilardi D, Furfaro F, Danese S. JAK inhibitors: Novel developments in management of ulcerative colitis. Best Pract Res Clin Gastroenterol 2018;32-33:89-93. [PMID: 30060943 DOI: 10.1016/j.bpg.2018.05.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
9 Macaluso FS, Maida M, Ventimiglia M, Renna S, Cottone M, Orlando A. Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. Inflamm Bowel Dis 2019;25:987-97. [PMID: 30590590 DOI: 10.1093/ibd/izy365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
10 Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatology (Oxford) 2021;60:ii45-51. [PMID: 33950226 DOI: 10.1093/rheumatology/keaa896] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pugliese N, Roda G, Peyrin-biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs 2020;25:71-9. [DOI: 10.1080/14728214.2020.1737009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Troncone E, Monteleone G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin Drug Saf 2017;16:779-89. [PMID: 28608717 DOI: 10.1080/14740338.2017.1340936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
13 Macaluso FS, Orlando A. Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective? Minerva Gastroenterol Dietol 2019;65. [DOI: 10.23736/s1121-421x.19.02617-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Lucaciu LA, Seicean R, Seicean A. Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? - a systematic review. Eur J Gastroenterol Hepatol 2020;32:669-77. [PMID: 32282548 DOI: 10.1097/MEG.0000000000001730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Schultheiss JPD, Mahmoud R, Louwers JM, van der Kaaij MT, van Hellemondt BP, van Boeckel PG, Mahmmod N, Jharap B, Fidder HH, Oldenburg B. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2021;54:1298-308. [PMID: 34559428 DOI: 10.1111/apt.16605] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Hvas CL, Bendix M, Dige A, Dahlerup JF, Agnholt J. Current, experimental, and future treatments in inflammatory bowel disease: a clinical review. Immunopharmacol Immunotoxicol 2018;40:446-60. [PMID: 29745777 DOI: 10.1080/08923973.2018.1469144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
17 Macaluso FS, Maida M, Grova M, Crispino F, Teresi G, Orlando A, Orlando A. Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. Therap Adv Gastroenterol 2021;14:17562848211010668. [PMID: 33995582 DOI: 10.1177/17562848211010668] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Olivera P, Danese S, Peyrin-biroulet L. JAK inhibition in inflammatory bowel disease. Expert Review of Clinical Immunology 2017;13:693-703. [DOI: 10.1080/1744666x.2017.1291342] [Cited by in Crossref: 46] [Cited by in F6Publishing: 20] [Article Influence: 9.2] [Reference Citation Analysis]
19 Verstockt B, Vetrano S, Salas A, Nayeri S, Duijvestein M, Vande Casteele N, Danese S, D’haens G, Eckmann L, Faubion WA, Feagan BG, Jairath V, Ma C, Mcgovern D, Panes J, Sandborn WJ, Silverberg MS, Vermeire S; Alimentiv Translational Research Consortium (ATRC). Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. [DOI: 10.1038/s41575-021-00574-7] [Reference Citation Analysis]
20 Ashton JJ, Ennis S, Beattie RM. Early-onset paediatric inflammatory bowel disease. The Lancet Child & Adolescent Health 2017;1:147-58. [DOI: 10.1016/s2352-4642(17)30017-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
21 Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease. J Crohns Colitis 2020;14:1090-102. [PMID: 32119090 DOI: 10.1093/ecco-jcc/jjaa039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
22 Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00377-0. [PMID: 34856198 DOI: 10.1016/S2468-1253(21)00377-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Romano C, Esposito S, Ferrara R, Cuomo G. Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy 2020;20:49-62. [DOI: 10.1080/14712598.2020.1689953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
24 Panés J, Salas A. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. J Crohns Colitis 2018;12:S633-40. [PMID: 30137311 DOI: 10.1093/ecco-jcc/jjy011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
25 Danese S, Peyrin-Biroulet L. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. Inflamm Bowel Dis 2021:izab135. [PMID: 34089259 DOI: 10.1093/ibd/izab135] [Reference Citation Analysis]
26 Danese S, D'Amico F, Bonovas S, Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis 2018;24:2106-12. [PMID: 29697791 DOI: 10.1093/ibd/izy076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
27 Katsanos KH, Papamichael K, Feuerstein JD, Christodoulou DK, Cheifetz AS. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clin Immunol 2019;206:9-14. [PMID: 29545207 DOI: 10.1016/j.clim.2018.03.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
28 Effenberger M, Reider S, Waschina S, Bronowski C, Enrich B, Adolph TE, Koch R, Moschen AR, Rosenstiel P, Aden K, Tilg H. Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients. J Crohns Colitis 2021;15:88-98. [PMID: 32687146 DOI: 10.1093/ecco-jcc/jjaa152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
29 Wijnands AM, Mahmoud R, Lutgens MWMD, Oldenburg B. Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives. Eur J Intern Med 2021;93:35-41. [PMID: 34481721 DOI: 10.1016/j.ejim.2021.08.010] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
30 Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, Jairath V. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:5-23. [DOI: 10.1111/apt.15297] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
31 Binienda A, Fichna J, Salaga M. Recent advances in inflammatory bowel disease therapy. European Journal of Pharmaceutical Sciences 2020;155:105550. [DOI: 10.1016/j.ejps.2020.105550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Fiocchi C, Iliopoulos D. What's new in IBD therapy: An "omics network" approach. Pharmacol Res 2020;159:104886. [PMID: 32428668 DOI: 10.1016/j.phrs.2020.104886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
33 Rodríguez-Lago I, Benítez JM, García-Sánchez V, Gutiérrez A, Sempere L, Ginard D, Barreiro-de Acosta M, Cabriada JL. Granulocyte and monocyte apheresis in inflammatory bowel disease: The patients' point of view. Gastroenterol Hepatol 2018;41:423-31. [PMID: 29739692 DOI: 10.1016/j.gastrohep.2018.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
34 Panés J, Gisbert JP. Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. Gastroenterología y Hepatología 2019;42:403-12. [DOI: 10.1016/j.gastrohep.2019.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
35 Parigi TL, D'Amico F, Danese S. Upadacitinib for Crohn's Disease and Ulcerative Colitis Treatment: Hitting the Selective JAKpot. Gastroenterology 2021;160:1472-4. [PMID: 32311362 DOI: 10.1053/j.gastro.2020.04.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
37 Macaluso FS, Fries W, Privitera AC, Cappello M, Siringo S, Inserra G, Magnano A, Di Mitri R, Mocciaro F, Belluardo N, Scarpulla G, Magrì G, Trovatello A, Carroccio A, Genova S, Bertolami C, Vassallo R, Romano C, Citrano M, Accomando S, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Porcari S, Ferracane C, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Diseases [SN-IBD]. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. J Crohns Colitis 2019;13:209-17. [PMID: 30295785 DOI: 10.1093/ecco-jcc/jjy156] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
38 Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:323-37. [PMID: 32203403 DOI: 10.1038/s41575-020-0273-0] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 31.5] [Reference Citation Analysis]
39 Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol 2019;10:212. [PMID: 30930775 DOI: 10.3389/fphar.2019.00212] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 13.7] [Reference Citation Analysis]
40 Roda G, Dal Buono A, Argollo M, Danese S. JAK selectivity: more precision less troubles. Expert Rev Gastroenterol Hepatol 2020;14:789-96. [PMID: 32520647 DOI: 10.1080/17474124.2020.1780120] [Reference Citation Analysis]
41 Dell'Avalle C, D'Amico F, Gabbiadini R, Dal Buono A, Pugliese N, Zilli A, Furfaro F, Fiorino G, Allocca M, Peyrin-Biroulet L, Danese S. JAK inhibitors in crohn's disease: ready to go? Expert Opin Investig Drugs 2022;31:145-61. [PMID: 35164629 DOI: 10.1080/13543784.2022.2032639] [Reference Citation Analysis]
42 Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 2019;79:1321-35. [PMID: 31317509 DOI: 10.1007/s40265-019-01169-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
43 Lefevre PLC, Vande Casteele N. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S725-36. [PMID: 32160283 DOI: 10.1093/ecco-jcc/jjaa014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
44 Danese S. New Drugs in the Ulcerative Colitis Pipeline: Prometheus Unbound. Gastroenterology 2020;158:467-70. [PMID: 31862200 DOI: 10.1053/j.gastro.2019.12.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, Ansari A. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom. BMC Gastroenterol 2020;20:296. [PMID: 32917155 DOI: 10.1186/s12876-020-01441-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Chaudhary CL, Chaudhary P, Dahal S, Bae D, Nam TG, Kim JA, Jeong BS. Inhibition of colitis by ring-modified analogues of 6-acetamido-2,4,5-trimethylpyridin-3-ol. Bioorg Chem 2020;103:104130. [PMID: 32745758 DOI: 10.1016/j.bioorg.2020.104130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Danese S, Argollo M, Le Berre C, Peyrin-Biroulet L. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut 2019;68:1893-9. [PMID: 31227590 DOI: 10.1136/gutjnl-2019-318448] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
48 Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, Danese S. Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther 2020;20:413-20. [PMID: 32093531 DOI: 10.1080/14712598.2020.1732919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
49 Pouillon L, Bossuyt P, Vanderstukken J, Moulin D, Netter P, Danese S, Jouzeau JY, Loeuille D, Peyrin-Biroulet L. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol. 2017;10:1363-1374. [PMID: 28879780 DOI: 10.1080/17512433.2017.1377609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
50 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
51 Macaluso FS, Orlando A, Cottone M. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. Expert Opin Biol Ther 2019;19:89-98. [PMID: 30571147 DOI: 10.1080/14712598.2019.1561850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
52 Macaluso FS, Maida M, Ventimiglia M, Cottone M, Orlando A. Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. Expert Opin Biol Ther 2020;20:193-203. [PMID: 31859538 DOI: 10.1080/14712598.2020.1707800] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
53 Hazel K, O'Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis 2020;11:2040622319899297. [PMID: 32076497 DOI: 10.1177/2040622319899297] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
54 Ciccocioppo R, Baumgart DC, Dos Santos CC, Galipeau J, Klersy C, Orlando G. Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). Cytotherapy 2019;21:824-39. [PMID: 31201092 DOI: 10.1016/j.jcyt.2019.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
55 López-Sanromán A, Esplugues JV, Domènech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol 2021;44:39-48. [PMID: 32829958 DOI: 10.1016/j.gastrohep.2020.04.012] [Reference Citation Analysis]
56 Elkin M. Role of Heparanase in Macrophage Activation. Adv Exp Med Biol 2020;1221:445-60. [PMID: 32274721 DOI: 10.1007/978-3-030-34521-1_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
57 White JR, Phillips F, Monaghan T, Fateen W, Samuel S, Ghosh S, Moran GW. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:1610-1622. [PMID: 29672874 DOI: 10.1111/apt.14669] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
58 Shukla T, Sands BE. Novel Non-biologic Targets for Inflammatory Bowel Disease. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0689-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
59 Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. Drug Des Devel Ther 2019;13:4091-105. [PMID: 31819376 DOI: 10.2147/DDDT.S182891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
60 Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology 2020; 158: 1554-1573. e12. [PMID: 31926171 DOI: 10.1053/j.gastro.2020.01.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 27.5] [Reference Citation Analysis]
61 Olivera P, Danese S, Jay N, Natoli G, Peyrin-Biroulet L. Big data in IBD: A look into the future. Nat Rev Gastroenterol Hepatol. 2019;. [PMID: 30659247 DOI: 10.1038/s41575-019-0102-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 15.3] [Reference Citation Analysis]
62 Chen Y, Zheng J, Qu C, Xiao Y, Li F, Jin Q, Li H, Meng F, Jin G, Jin D. Inonotus obliquus polysaccharide ameliorates dextran sulphate sodium induced colitis involving modulation of Th1/Th2 and Th17/Treg balance. Artificial Cells, Nanomedicine, and Biotechnology 2019;47:757-66. [DOI: 10.1080/21691401.2019.1577877] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
63 Morosi LG, Cutine AM, Cagnoni AJ, Manselle-Cocco MN, Croci DO, Merlo JP, Morales RM, May M, Pérez-Sáez JM, Girotti MR, Méndez-Huergo SP, Pucci B, Gil AH, Huernos SP, Docena GH, Sambuelli AM, Toscano MA, Rabinovich GA, Mariño KV. Control of intestinal inflammation by glycosylation-dependent lectin-driven immunoregulatory circuits. Sci Adv 2021;7:eabf8630. [PMID: 34144987 DOI: 10.1126/sciadv.abf8630] [Reference Citation Analysis]
64 Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L. Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther 2018;47:773-83. [PMID: 29349829 DOI: 10.1111/apt.14514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Moon SY, Kim KD, Yoo J, Lee JH, Hwangbo C. Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models. Molecules 2021;26:2824. [PMID: 34068714 DOI: 10.3390/molecules26092824] [Reference Citation Analysis]
66 Zatorski H, Nakov R. Faecal Microbiota Transplantation in Inflammatory Bowel Disease: Current Concepts and Future Challenges. Curr Drug Targets 2020;21:1440-7. [PMID: 32484770 DOI: 10.2174/1389450121666200602125507] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Teixeira FV, Damião AOMC, Kotze PG. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES. Arq Gastroenterol 2018;55:198-200. [PMID: 30043874 DOI: 10.1590/S0004-2803.201800000-36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
68 Tran V, Shammas RM, Sauk JS, Padua D. Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy. Clin Exp Gastroenterol 2019;12:179-91. [PMID: 31118734 DOI: 10.2147/CEG.S150908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]